Type 2 Diabetes Mellitus
Conditions
Interventions
Experimental group:Liraglutide treatment
Control group:Use non-GLP-1RA and non-DPP-4 inhibitors of hypoglycemic drugs
Sponsors
Tianjin Medical University Zhu Xianyi Memorial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meet the 1999 WHO diagnostic criteria for T2DM. 2. Follow up on time, agree and sign the informed consent form. 3. Aged 18-75 years.
Exclusion criteria
Exclusion criteria: 1. Patients who have used GLP-1RA or DPP-4 inhibitor drugs in the past 3 months. 2. Patients with new acute coronary syndrome and cerebrovascular accident in the past 3 months. 3. The patient has acute complications of diabetes, including diabetic ketoacidosis, hyperosmolar hyperglycemia syndrome, etc. 4. The patient is in a state of stress, such as infection, surgery, trauma, etc. 5. Patients with respiratory failure, heart failure and significant abnormalities in liver and kidney function, including Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) are 2 times higher than the upper limit of normal, and the glomerular filtration rate is less than 50 mL/min/1.73 m^2.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Microvesicles; | — |
Countries
China
Contacts
Public ContactZhang Jingyun
Tianjin Medical University Zhu Xianyi Memorial Hospital
Outcome results
None listed